THANK YOU FOR SUBSCRIBING
The LaBahn Pancreatic Cancer Program at the Medical College of Wisconsin in Milwaukee has begun a clinical trial with generous funding from the Seena Magowitz Foundation
FREMONT, CA: Scientists have recently identified pancreatic cancer as having two different molecular subtypes (classical and basal-like); such subgroups could be predictive of chemotherapy response. The LaBahn Pancreatic Cancer Program at the Medical College of Wisconsin in Milwaukee has begun a clinical trial with generous funding from the Seena Magowitz Foundation, which uses state-of-the-art molecular subtyping of endoscopic biopsy samples to direct treatment.
At the Medical College of Wisconsin, Honor Health Research Institute in Scottsdale, Arizona, the Translational Genomics Research Institute in Phoenix, and the University of North Carolina, this multi-center trial will be performed. It is estimated that the study will recruit 41 patients. Patients will undergo a personalized chemotherapy program before surgery for pancreatic cancer following molecular subtype determination.
At the Medical College of Wisconsin in Milwaukee, the LaBahn Pancreatic Cancer Program is an internationally recognized program comprising a multidisciplinary team of doctors, scientists, and devoted staff who share a passion and urgency to make meaningful progress in the fight against pancreatic cancer. At each level of pancreatic cancer treatment, the program involves a full volume of clinical trials and has paved the way in novel investigator-initiated trials for operable pancreatic cancer patients.
About The Medical College of Wisconsin LaBahn Pancreatic Cancer Program
With the lowest survival rate of any tumor-type cancer, pancreatic cancer is a complicated illness. It's hard to combat, but not impossible. It can make all the difference to have the right team. At MCW, their team of doctors and medical professionals have gained international recognition for their work seeking ways to detect and treat pancreatic cancer.
The Seena Magowitz Foundation
The Seena Magowitz Foundation is known as The Face and Voice of Pancreatic Cancer and aims to offer the loudest voice of pancreatic cancer awareness. Roger created the foundation in honor of his mother, Seena Magowitz, who lost her fight with pancreatic cancer in 2001, E. Magowitz added.
The foundation is approaching its 20th year of medical research funding to hunt for new life-extension therapies for patients with pancreatic cancer. In addition to leading-edge treatments, with an overarching goal of discovering a cure, it focuses on finding simpler early detection methods.